S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
NASDAQ:ONVO

Organovo - ONVO Stock Forecast, Price & News

$3.04
-0.23 (-7.03%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.92
$3.20
50-Day Range
$1.71
$3.55
52-Week Range
$1.71
$8.13
Volume
47,291 shs
Average Volume
66,048 shs
Market Capitalization
$26.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ONVO stock logo

About Organovo (NASDAQ:ONVO) Stock

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Organovo in a research report on Tuesday, August 9th. They set a "sell" rating on the stock.

Organovo Trading Down 0.6 %

Shares of ONVO opened at $3.26 on Monday. Organovo has a 52 week low of $1.71 and a 52 week high of $8.13. The firm's 50-day simple moving average is $2.54 and its 200 day simple moving average is $2.94.

Organovo (NASDAQ:ONVO - Get Rating) last announced its quarterly earnings results on Friday, June 10th. The medical research company reported ($0.22) EPS for the quarter. The company had revenue of $1.50 million for the quarter.

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Stock News Headlines

StockNews.com Begins Coverage on Organovo (NASDAQ:ONVO)
Organovo Holdings Inc (ONVO)
See More Headlines
Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Company Calendar

Last Earnings
6/10/2022
Today
8/16/2022
Next Earnings (Estimated)
8/19/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-11,450,000.00
Pretax Margin
-808.47%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$3.47 per share

Miscellaneous

Free Float
8,364,000
Market Cap
$26.48 million
Optionable
Optionable
Beta
1.10

Key Executives

  • Mr. Keith E. Murphy (Age 50)
    Exec. Chairman & Principal Exec. Officer
    Comp: $397.18k
  • Dr. Jeffrey N. Miner (Age 60)
    Chief Scientific Officer
    Comp: $221.09k
  • Mr. Thomas Einar Jurgensen J.D. (Age 65)
    MS, Gen. Counsel & Corp. Sec.
    Comp: $264.86k
  • Mr. Thomas P. Hess CPA (Age 58)
    MBA, Chief Financial Officer
  • Dr. Curtis M. Tyree Ph.D.
    Sr. VP of Strategy & Bus. Devel.













ONVO Stock - Frequently Asked Questions

How have ONVO shares performed in 2022?

Organovo's stock was trading at $3.63 at the start of the year. Since then, ONVO stock has decreased by 16.3% and is now trading at $3.04.
View the best growth stocks for 2022 here
.

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 19th 2022.
View our ONVO earnings forecast
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) announced its earnings results on Friday, June, 10th. The medical research company reported ($0.22) EPS for the quarter. The medical research company earned $1.50 million during the quarter.

When did Organovo's stock split?

Organovo shares reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (5.33%), Sumitomo Mitsui Trust Holdings Inc. (5.33%), ARK Investment Management LLC (3.35%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Douglas Jay Cohen and Steven George Hughes.
View institutional ownership trends
.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $3.04.

How much money does Organovo make?

Organovo (NASDAQ:ONVO) has a market capitalization of $26.48 million and generates $1.50 million in revenue each year. The medical research company earns $-11,450,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com.

This page (NASDAQ:ONVO) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.